Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Analyst Performance
Any
Analyst Rating
Any
Upside / Downside
Any
Action
Any
Market Cap
Any
Analyst & Firm | Company | Price | Rating & Price Target | Upside / Downside | Success Rate | Average Return | Action | Date | Article |
|---|---|---|---|---|---|---|---|---|---|
 | Evolent Health | BUY $20 | ― | -5.70% | Reiterated | RBC Capital Sticks to Its Buy Rating for Evolent Health (EVH) | |||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | HOLD $16 | ― | 5.40% | Assigned | ||||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $210 | ― | 5.40% | Assigned | ||||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $4 | ― | 19.10% | Assigned | ||||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $132→$127 | ― | 8.20% | Reiterated | ||||
| United Airlines Holdings | BUY $84→$100 | ― | -0.20% | Reiterated | United Airlines price target raised to $100 from $84 at BofA | |||
| Delta Air Lines | BUY $60→$72 | ― | -0.20% | Reiterated | Delta Air Lines price target raised to $72 from $60 at BofA | |||
 | VEON | BUY $48 | ― | -1.10% | Initiated | Veon initiated with a Buy at Benchmark | |||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $28→$32 | ― | 10.30% | Reiterated | ||||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $28→$31 | ― | 10.30% | Reiterated | ||||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $7 | ― | 4.70% | Assigned | ||||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | SELL $6 | ― | 19.10% | Assigned | ||||
 | Beyond Air | BUY $1 | ― | -4.80% | Assigned | Piper Sandler Releases a Buy Rating on Beyond Air (XAIR) | |||
| Illumina | BUY $170→$184 | ― | -3.50% | Reiterated | Illumina price target raised to $184 from $170 at Stephens | |||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $130→$146 | ― | 12.60% | Reiterated | ||||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $135 | ― | 19.10% | Assigned | ||||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $72→$70 | ― | 12.60% | Reiterated | ||||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | HOLD $40→$70 | ― | 5.40% | Reiterated | ||||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $49→$48 | ― | 12.60% | Reiterated | ||||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $45→$43 | ― | 9.20% | Reiterated | ||||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $42 | ― | 19.10% | Assigned | ||||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $36→$40 | ― | 12.60% | Reiterated | ||||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $10→$8 | ― | 12.60% | Reiterated | ||||
| Taysha Gene Therapies | BUY $6 | ― | -0.70% | Reiterated | Buy Rating Affirmed for Taysha Gene Therapies Amid Promising TSHA-102 Trial Results | |||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $75 | ― | 27.60% | Assigned | ||||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $54→$72 | ― | 14.70% | Reiterated | ||||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | HOLD $35→$37 | ― | 55.10% | Reiterated | ||||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $13→$16 | ― | 8.20% | Reiterated | ||||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | SELL $16→$12 | ― | 12.10% | Reiterated | ||||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $10→$9 | ― | 8.20% | Reiterated | ||||
Jash PatwaJ.P. Morgan Not Ranked | Luminar Technologies | BUY $6 | ― | ― | Reiterated | Optimistic Buy Rating for Luminar Technologies: Strategic Advancements and Strong Market Position | |||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | HOLD $85 | ― | 4.20% | Reiterated | ||||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $33 | ― | 39.40% | Reiterated | ||||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $10 | ― | 0.90% | Reiterated | ||||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $28 | ― | 6.20% | Reiterated | ||||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | HOLD $265→$270 | ― | 8.60% | Reiterated | ||||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $42→$48 | ― | 16.00% | Reiterated | ||||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | HOLD $38→$44 | ― | 15.80% | Reiterated | ||||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $26 | ― | 18.10% | Reiterated | ||||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $23→$26 | ― | 5.70% | Reiterated | ||||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | HOLD $5→$6 | ― | 4.50% | Reiterated | ||||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $4→$2 | ― | 14.00% | Reiterated | ||||
| Live Nation Entertainment | BUY $144 | ― | -1.10% | Assigned | Analysts Conflicted on These Communication Services Names: IAC/InteractiveCorp. (NASDAQ: IAC), Live Nation Entertainment (NYSE: LYV) and REA Group Ltd (Other OTC: RPGRF) | |||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $6 | ― | 16.30% | Assigned | ||||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $92 | ― | 15.10% | Assigned | ||||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $20 | ― | 10.30% | Assigned | ||||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $17 | ― | 15.10% | Assigned | ||||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $25 | ― | 10.30% | Assigned | ||||
| Clinigence Holdings | BUY $60 | ― | -7.50% | Assigned | Benchmark Co. Reaffirms Their Buy Rating on Clinigence Holdings (NUTX) | |||
| Alkermes | BUY $35 | ― | -4.60% | Reiterated | TD Cowen Sticks to Their Buy Rating for Alkermes (ALKS) |
Rows:
